Calcium acetate/magnesium carbonate - Fresenius Medical Care

Drug Profile

Calcium acetate/magnesium carbonate - Fresenius Medical Care

Alternative Names: OsvaRen; Rephoren

Latest Information Update: 14 Jul 2015

Price : $50

At a glance

  • Originator Fresenius Medical Care
  • Class Acetates; Elements; Inorganic chemicals; Small molecules
  • Mechanism of Action Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperphosphataemia

Most Recent Events

  • 01 Jun 2015 Fresenius Medical Care completes a phase II/III trial in Hyperphosphataemia in Germany (NCT02027662)
  • 01 Jan 2014 Phase-II/III clinical trials in Hyperphosphataemia in Germany (PO, granules)
  • 23 Jun 2010 Efficacy and adverse events data from the CALMAG study in patients with chronic kidney disease on haemodialysis released by Fresenius Medical Care
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top